Journal of Molecular and Cellular Cardiology
Volume 48, Issue 6 , Pages 1111-1120 , June 2010

Molecular determinants of Kv1.5 channel block by diphenyl phosphine oxide-1

  • Yi-mei Du

      Affiliations

    • Research Center of Ion Channelopathy, Institute of Cardiovascular Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 Jiefang Ave, Wuhan 430022, China
    • Yi-mei Du, Xiao-xian Zhang, and Dan-na Tu contribute equally to this paper.
    • ,
  • Xiao-xian Zhang

      Affiliations

    • Research Center of Ion Channelopathy, Institute of Cardiovascular Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 Jiefang Ave, Wuhan 430022, China
    • Yi-mei Du, Xiao-xian Zhang, and Dan-na Tu contribute equally to this paper.
    • ,
  • Dan-na Tu

      Affiliations

    • Research Center of Ion Channelopathy, Institute of Cardiovascular Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 Jiefang Ave, Wuhan 430022, China
    • Yi-mei Du, Xiao-xian Zhang, and Dan-na Tu contribute equally to this paper.
    • ,
  • Ning Zhao

      Affiliations

    • Research Center of Ion Channelopathy, Institute of Cardiovascular Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 Jiefang Ave, Wuhan 430022, China
    • ,
  • Yan-jie Liu

      Affiliations

    • Laboratory Department and Institute of Immunology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 Jiefang Ave, Wuhan 430022, China
    • ,
  • Hua Xiao

      Affiliations

    • Research Center of Ion Channelopathy, Institute of Cardiovascular Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 Jiefang Ave, Wuhan 430022, China
    • ,
  • Michael C. Sanguinetti

      Affiliations

    • Nora Eccles Harrison Cardiovascular Research and Training Institute, Department of Physiology, University of Utah, Salt Lake City, UT 84112, USA
    • ,
  • Anruo Zou

      Affiliations

    • Research Center of Ion Channelopathy, Institute of Cardiovascular Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 Jiefang Ave, Wuhan 430022, China
    • Corresponding Author InformationCorresponding authors. Tel.: +86 27 85726376; fax: +86 27 85726340.
    • ,
  • Yu-hua Liao

      Affiliations

    • Research Center of Ion Channelopathy, Institute of Cardiovascular Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 Jiefang Ave, Wuhan 430022, China
    • Corresponding Author InformationCorresponding authors. Tel.: +86 27 85726376; fax: +86 27 85726340.

Received 20 May 2009 ,Revised 9 February 2010 ,Accepted 12 February 2010.

References 

  1. Choudhury A, Lip GY. Antiarrhythmic drugs in atrial fibrillation: an overview of new agents, their mechanisms of action and potential clinical utility. Expert Opin Investig Drugs. 2004;13:841–855
  2. Fedida D, Wible B, Wang Z, Fermini B, Faust F, Nattel S, et al. Identity of a novel delayed rectifier current from human heart with a cloned K+ channel current. Circ Res. 1993;73:210–216
  3. Peukert S, Brendel J, Pirard B, Bruggemann A, Below P, Kleemann HW, et al. Identification, synthesis, and activity of novel blockers of the voltage-gated potassium channel Kv1.5. J Med Chem. 2003;46:486–498
  4. Amos GJ, Wettwer E, Metzger F, Li Q, Himmel HM, Ravens U. Differences between outward currents of human atrial and subepicardial ventricular myocytes. J Physiol. 1996;491(Pt 1):31–50
  5. Nattel S, Carlsson L. Innovative approaches to anti-arrhythmic drug therapy. Nat Rev Drug Discov. 2006;5:1034–1049
  6. Trotter BW, Nanda KK, Kett NR, Regan CP, Lynch JJ, Stump GL, et al. Design and synthesis of novel isoquinoline-3-nitriles as orally bioavailable Kv1.5 antagonists for the treatment of atrial fibrillation. J Med Chem. 2006;49:6954–6957
  7. Ford JW, Milnes JT. New drugs targeting the cardiac ultra-rapid delayed-rectifier current (IKur): rationale, pharmacology and evidence for potential therapeutic value. J Cardiovasc Pharmacol. 2008;52:105–120
  8. Decher N, Pirard B, Bundis F, Peukert S, Baringhaus KH, Busch AE, et al. Molecular basis for Kv1.5 channel block: conservation of drug binding sites among voltage-gated K+ channels. J Biol Chem. 2004;279:394–400
  9. Decher N, Kumar P, Gonzalez T, Pirard B, Sanguinetti MC. Binding site of a novel Kv1.5 blocker: a “foot in the door” against atrial fibrillation. Mol Pharmacol. 2006;70:1204–1211
  10. Arechiga IA, Barrio-Echavarria GF, Rodriguez-Menchaca AA, Moreno-Galindo EG, Decher N, Tristani-Firouzi M, et al. Kv1.5 open channel block by the antiarrhythmic drug disopyramide: molecular determinants of block. J Pharmacol Sci. 2008;108:49–55
  11. Strutz-Seebohm N, Gutcher I, Decher N, Steinmeyer K, Lang F, Seebohm G. Comparison of potent Kv1.5 potassium channel inhibitors reveals the molecular basis for blocking kinetics and binding mode. Cell Physiol Biochem. 2007;20:791–800
  12. Stump GL, Wallace AA, Regan CP, Lynch JJ. In vivo antiarrhythmic and cardiac electrophysiologic effects of a novel diphenylphosphine oxide IKur blocker (2-isopropyl-5-methylcyclohexyl) diphenylphosphine oxide. J Pharmacol Exp Ther. 2005;315:1362–1367
  13. Regan CP, Wallace AA, Cresswell HK, Atkins CL, Lynch JJ. In vivo cardiac electrophysiologic effects of a novel diphenylphosphine oxide IKur blocker, (2-isopropyl-5-methylcyclohexyl) diphenylphosphine oxide, in rat and nonhuman primate. J Pharmacol Exp Ther. 2006;316:727–732
  14. Lagrutta A, Wang J, Fermini B, Salata JJ. Novel, potent inhibitors of human Kv1.5 K+ channels and ultrarapidly activating delayed rectifier potassium current. J Pharmacol Exp Ther. 2006;317:1054–1063
  15. Karczewski J, Kiss L, Kane SA, Koblan KS, Lynch RJ, Spencer RH. High-throughput analysis of drug binding interactions for the human cardiac channel, Kv1.5. Biochem Pharmacol. 2009;77:177–185
  16. Wang X, Liao Y, Zou A, Li L, Tu D. Blockade action of ketanserin and increasing effect of potassium ion on Kv1.3 channels expressed in Xenopus oocytes. Pharmacol Res. 2007;56:148–154
  17. Tu DN, Liao YH, Zou AR, Du YM, Run Q, Wang XP, et al. Electropharmacological properties of telmisartan in blocking hKv1.5 and HERG potassium channels expressed on Xenopus laevis oocytes. Acta Pharmacol Sin. 2008;29:913–922
  18. Du Y, Zhang S, Wu H, Zou A, Lei M, Cheng L, et al. Glycyrretinic acid blocks cardiac sodium channels expressed in Xenopus oocytes. J Ethnopharmacol. 2009;125:318–323
  19. Sanchez-Chapula JA, Navarro-Polanco RA, Culberson C, Chen J, Sanguinetti MC. Molecular determinants of voltage-dependent human ether-a-go-go related gene (HERG) K+ channel block. J Biol Chem. 2002;277:23587–23595
  20. Decher N, Kumar P, Gonzalez T, Renigunta V, Sanguinetti MC. Structural basis for competition between drug binding and Kvbeta 1.3 accessory subunit-induced N-type inactivation of Kv1.5 channels. Mol Pharmacol. 2005;68:995–1005
  21. Eldstrom J, Wang Z, Xu H, Pourrier M, Ezrin A, Gibson K, et al. The molecular basis of high-affinity binding of the antiarrhythmic compound vernakalant (RSD1235) to Kv1.5 channels. Mol Pharmacol. 2007;72:1522–1534
  22. Yeola SW, Rich TC, Uebele VN, Tamkun MM, Snyders DJ. Molecular analysis of a binding site for quinidine in a human cardiac delayed rectifier K+ channel. Role of S6 in antiarrhythmic drug binding. Circ Res. 1996;78:1105–1114
  23. Franqueza L, Longobardo M, Vicente J, Delpon E, Tamkun MM, Tamargo J, et al. Molecular determinants of stereoselective bupivacaine block of hKv1.5 channels. Circ Res. 1997;81:1053–1064
  24. Caballero R, Moreno I, Gonzalez T, Valenzuela C, Tamargo J, Delpon E. Putative binding sites for benzocaine on a human cardiac cloned channel (Kv1.5). Cardiovasc Res. 2002;56:104–117
  25. Ander M, Luzhkov VB, Aqvist J. Ligand binding to the voltage-gated Kv1.5 potassium channel in the open state—docking and computer simulations of a homology model. Biophys J. 2008;94:820–831
  26. Long SB, Campbell EB, Mackinnon R. Crystal structure of a mammalian voltage-dependent Shaker family K+ channel. Science. 2005;309:897–903
  27. Kamiya K, Niwa R, Mitcheson JS, Sanguinetti MC. Molecular determinants of HERG channel block. Mol Pharmacol. 2006;69:1709–1716
  28. Leicher T, Bahring R, Isbrandt D, Pongs O. Coexpression of the KCNA3B gene product with Kv1.5 leads to a novel A-type potassium channel. J Biol Chem. 1998;273:35095–35101
  29. Decher N, Gonzalez T, Streit AK, Sachse FB, Renigunta V, Soom M, et al. Structural determinants of Kvbeta1.3-induced channel inactivation: a hairpin modulated by PIP(2). EMBO J. 2008;27:3164–3174

PII: S0022-2828(10)00045-3

doi: 10.1016/j.yjmcc.2010.02.010

Journal of Molecular and Cellular Cardiology
Volume 48, Issue 6 , Pages 1111-1120 , June 2010

Article Tools

* Image Usage & Resolution